Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2026

	30.09.2026	31.12.2025
ASSETS	***EUR'000***	***EUR'000***
Non-current assets		
Property, plant and equipment	17 085	17 889
Intangible assets	1 837	1 844
Investments in subsidiaries	34	34
Trade receivables	2 603	2 603
Total non-current assets	**21 559**	**22 370**
Current assets		
Inventories	8 717	9 165
Trade and other receivables	44 028	40 466
Cash and cash equivalents	28	577
Total current assets	**52 773**	**50 208**
Total assets	**74 332**	**72 578**
LIABILITIES		
Equity		
Share capital	51 663	49 033
Reserves	7 846	7 525
Retained earnings	3 920	3 075
Total	**63 429**	**59 634**
Non-current liabilities		
Long-term loans	506	789
Deferred tax liabilities	637	637
Retirement benefit obligations	182	182
Total non-current liabilities	**1 325**	**1 608**
Current liabilities		
Trade and other liabilities	4 629	5 590
Short-term loans	4 003	4 752
Current portion of long-term loans	398	476
Current corporate income tax		29
Other tax liabilities	548	489
Total current liabilities	**9 578**	**11 337**
Total liabilities	**10 903**	**12 944**
Total equity and liabilities	**74 332**	**72 578**

Date of preparation: 28.10.2026
Sofia

Prepared by:.....
/Tsvetelina Pandeva/

Executive Director:.....
/Biser Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2026

	30.09.2026	**30.09.2025**
	EUR'000	***EUR'000***
Revenue	30 345	24 534
Other income	1	1
Total income	**30 346**	**24 535**
Carrying amount of goods sold	(1 372)	(1 156)
Changes in inventories of finished products and work in progress	642	7
Materials and services	(19 295)	(14 226)
Personnel expenses	(4 438)	(4 023)
Depreciation / amortisation expenses	(1 118)	(1 089)
Other expenses	(448)	(240)
Finance income	12	40
Finance costs	(202)	(221)
Total expenses	**(26 219)**	**(20 908)**
Profit before taxation	**4 127**	**3 627**
Corporate income tax expense	(330)	(253)
Profit/Loss for the period	**3 797**	**3 374**
Total comprehensive income for the period	**3 797**	**3 374**
Earnings per share / in EUR per 1 share /	0.04	0.04

Date of preparation: 28.10.2026
Sofia

Prepared by:.....
/ Tsvetelina Pandeva /

Executive Director:.....
/Biser Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2026

	30.09.2026	30.09.2025
	EUR'000	*EUR'000*
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	18 562	18 117
Payments to suppliers of materials, goods and services	(9 780)	(9 746)
Payments to personnel	(4 487)	(4 101)
Foreign currency exchange gains/losses	(14)	(11)
Payments of interest and dividends	(359)	(187)
Other proceeds / payments	(3 372)	(3 089)
Net cash flows	**550**	**983**
Cash flows from investing activities		
Payments on non-current assets acquired	(176)	(499)
Net cash flows	**(176)**	**(499)**
Cash flows from financial activities		
Proceeds from loans	125	174
Payments on loans	(874)	(175)
Payment of interest, dividends	(130)	(200)
Payments on finance lease	(44)	(165)
Net cash flows	**(923)**	**(367)**
Change in cash and cash equivalents	**(549)**	**118**
Cash and cash equivalents at the beginning of the period	**577**	**40**
Cash and cash equivalents at the end of the period	**28**	**159**

Date of preparation: 28.10.2026
Sofia

Prepared by:..... .....
/ Tsvetelina Pandeva /

Executive Director:.....
/Biser Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2026

	Registered (share) capital *EUR'000*	Revaluation reserves *EUR'000*	Other reserves *EUR'000*	Retained earnings / loss *EUR'000*	Total equity *EUR'000*
Balance as of 01.01.2025	**46 937**	**2 208**	**4 488**	**2 327**	**55 960**
Profit/loss for the period				3 075	**3 075**
Other comprehensive income		598			**598**
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		**598**		**3 075**	**3 673**
Issue of shares by the owners	2 096		231	(2 327)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period	**2 096**		**231**	**(2 327)**	
Balance as of 31.12.2025	**49 033**	**2 806**	**4 719**	**3 075**	**59 633**
Balance as of 01.01.2026	**49 033**	**2 806**	**4 719**	**3 075**	**59 633**
Profit/loss for the period				3 797	**3 797**
Other comprehensive income				(1)	**(1)**
Total comprehensive income				**3 796**	**3 796**
Issue of shares by the owners	2 630			(2 630)	
Retained Earnings Transferred to Reserves			321	(321)	
Total amount of income and expenses recognised during the period	**2 630**		**321**	**(2 951)**	
Balance as of 30.09.2026	**51 663**	**2 806**	**5 040**	**3 920**	**63 429**

Date of preparation: 28.10.2026
Sofia

Prepared by:.....
/ Tsvetelina Pandeva /

Executive Director:.....
/Biser Georgiev /